Dr. Sobha Kurian, MD

Dr. Kurian practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Kurian's NPI, 1861505232, was assigned on August 17, 2006. Dr. Kurian holds West Virginia license 20120.

Dr. Kurian's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Kurian's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Kurian is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Kurian to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kurian practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kurian's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kurian is licensed in West Virginia.

CMS data shows 177 Medicare services from Dr. Kurian across 4 procedure codes in 2024, all of them office visits, for 118 Medicare patients. Medicare paid $15,059 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 118 Medicare patients who saw Dr. Kurian in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have cancer, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kurian's median patient age at 69, with 85% women.

In 2024, Dr. Kurian wrote 377 Medicare Part D claims for 106 patients. 70% of them were for generic drugs. CMS names the drug for 315 of them, across 10 drugs with 11 or more claims each, at $826,068 in total drug cost. In 2023, CMS named 457 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Kurian for performance year 2024, reported through an alternative payment model (APM). Dr. Kurian accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 13 papers to Dr. Kurian, published from 2013 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Colorectal Neoplasms and Survivors. Dr. Kurian's most frequent co-authors are Lubna Naaz Chaudhary, MD, Joanne Lorraine Blum, MD and Joshua Ross Dower, MD.

Dmand AI links Dr. Kurian to 7 clinical trials, 6 of them phase 3 studies. 6 are still active or recruiting. Conditions studied include Breast Neoplasms, Triple Negative Breast Neoplasms and Breast Diseases. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 9 general payments to Dr. Kurian from 6 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 76% of the total. Pfizer Inc. paid the most, $1,270. It also lists 6 research payments totaling $6,680 from 2021 to 2024.